Provides significant financial flexibility by retiring near-term debt maturities, deferring principal redemption payments, and further reducing near-term cash needs SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ: BNGO ) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024.